Lipanthyl (Fenofibrate)

Lipanthyl (fenofibrate) is used to manage lipid disorders by reducing triglyceride‑rich lipoproteins.

• Hypertriglyceridemia: lowers very high triglyceride levels to reduce pancreatitis risk.
• Mixed dyslipidemia: decreases triglycerides and LDL‑cholesterol while modestly raising HDL‑cholesterol.
• Primary hypercholesterolemia (adjunct therapy): adds to statin treatment to improve overall lipid profile.

• Fenofibrate activates peroxisome proliferator‑activated receptor alpha (PPARα) in liver and muscle cells, enhancing transcription of genes involved in fatty‑acid oxidation. This increases lipolysis of triglyceride‑rich particles, accelerates clearance of very‑low‑density lipoproteins, and raises high‑density lipoprotein cholesterol, resulting in an overall improvement of the lipid profile.

Adverse reactions may occur with fenofibrate therapy and are categorized by frequency.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Elevated liver enzymes: mild increases in ALT or AST.
• Muscle pain: myalgia without severe weakness.
• Headache: mild to moderate intensity.
• Skin reactions: rash or pruritus.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Hepatotoxicity: significant liver injury with jaundice.
• Severe allergic reactions: anaphylaxis or angioedema.
• Gallstones: formation of biliary sludge or stones.
• Blood dyscrasias: thrombocytopenia or leukopenia.

Before initiating fenofibrate, consider the following safety measures.

• Liver function: assess baseline hepatic enzymes and monitor periodically.
• Renal function: evaluate kidney status, especially in patients with impairment.
• Muscle health: avoid use with statins or other myotoxic agents without monitoring.
• Pregnancy and lactation: use only if the potential benefit justifies the risk.
• Drug interactions: review concomitant medications for known interactions.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Fenofibrate may interact with several drug classes; awareness of interaction severity guides management.

Major Interactions (Avoid)

• Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis.
• Anticoagulants (warfarin): potentiation of anticoagulant effect, monitor INR.
• Bile acid sequestrants: may reduce fenofibrate absorption, separate dosing by at least 2 hours.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (cyclosporine, tacrolimus): may raise fenofibrate levels.
• Oral hypoglycemics: potential enhancement of glucose‑lowering effect.
• Thyroid hormones: possible alteration of thyroid function tests.